Tel: 01789 267520

Biogen and Isis Pharmaceuticals provide community update on ISIS-SMNRx

08 October 2015

Biogen and Isis Pharmaceuticals have published a letter to the SMA community about the clinical development of their antisense oligonucleotide drug, ISIS-SMNRx.

The letter, which attempts to answer some of the frequently asked questions about ISIS-SMNRx and outline the current developmental status of the drug, can be found on the Cure SMA website here.

Further Information

Latest Isis press release on updated ISIS-SMNRx Phase II results

Initiation of second Phase III Isis trial

Initiation of original Phase III Isis Trial

Isis website

Biogen website